NanoVibronix Files Three U.S. Patent Applications Further Leveraging Its Innovative Surface Acoustic Wave Technology
January 19 2022 - 8:30AM
Business Wire
Creates Pathway to Launch of New Innovative
Products
NanoVibronix Inc., (NASDAQ: NAOV), a medical
device company that produces the UroShield® and PainShield® Surface
Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today
announced it has filed three U.S. patent applications with the U.S.
Patent & Trademark Office related to its SAW technology and
indwelling medical devices to protect targeted new product launches
and improvements to existing medical devices.
Brian Murphy, Chief Executive Officer of NanoVibronix Inc.,
commented, “Our patented SAW ultrasound technology has proven
effective in treating pain, as well as inhibiting infections
associated with urological conditions. Beyond just urology and pain
management, our expanding patent portfolio is driven by our
commitment to continue exploring different applications and
developing new products that leverage our unique technology.
“For example,” noted Murphy, “one of our new applications
relates to cosmetic applications of our technology to reduce signs
of aging and improve skin texture. In line with the growing use of
ultrasound in cosmetic dermatology, our SAW-generating devices and
facial patches address a host of cosmetic and topical concerns.
Importantly, this represents a new and sizeable market opportunity
for us.”
“In addition, we believe that we have made material improvements
to the assembly and operational configuration of indwelling medical
devices incorporating our SAW-generating technology,” added Murphy.
“The new patent applications provide for new stand-alone devices,
such as a novel catheter, intravenous (IV) needle assembly and
percutaneous endoscopic gastrostomy (PEG) tube. More generally,
described in the new applications is an ultrasound system that
effectively transforms any such indwelling medical device into a
therapeutic device. The generation of SAW along the surface of our
indwelling medical devices produces nano-vibrations sufficient to
inhibit the colonization of bacteria and, as a result, the
formation of bacterial biofilms that are commonly known to adhere
to surfaces of conventional indwelling devices. Therefore, we
believe that a significant improvement of our indwelling devices is
the accompanying antimicrobial prophylactic effect for preventing
infections associated with conventional indwelling medical devices.
Given that infections stemming from indwelling devices account for
up to twenty percent of annual healthcare-associated infections in
hospitalized patients, coupled with the resulting prolonged
hospitalization stays and increased costs per admission, our
technology should provide readily recognized and broadly applicable
advantages.”
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company
headquartered in Elmsford, New York, with research and development
in Nesher, Israel, focused on developing medical devices utilizing
its patented low intensity surface acoustic wave (SAW) technology.
The proprietary technology allows for the creation of low-frequency
ultrasound waves that can be utilized for a variety of medical
applications, including for disruption of biofilms and bacterial
colonization, as well as for pain relief. The Company’s primary
products include PainShield® and UroShield®, which are portable
devices suitable for administration at home without assistance of
medical professionals. Additional information about NanoVibronix is
available at: www.nanovibronix.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified; consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and
uncertainties associated with: (i) the geographic, social and
economic impact of COVID-19 on the Company’s ability to conduct its
business and raise capital in the future when needed, (ii) market
acceptance of our existing and new products or lengthy product
delays in key markets; (iii) negative or unreliable clinical trial
results; (iv) inability to secure regulatory approvals for the sale
of our products; (v) intense competition in the medical device
industry from much larger, multinational companies; (vi) product
liability claims; (vii) product malfunctions; (viii) our limited
manufacturing capabilities and reliance on subcontractor
assistance; (ix) insufficient or inadequate reimbursements by
governmental and/or other third party payers for our products; (x)
our ability to successfully obtain and maintain intellectual
property protection covering our products; (xi) legislative or
regulatory reform impacting the healthcare system in the U.S. or in
foreign jurisdictions; (xii) our reliance on single suppliers for
certain product components, (xiii) the need to raise additional
capital to meet our future business requirements and obligations,
given the fact that such capital may not be available, or may be
costly, dilutive or difficult to obtain; (xiv) our conducting
business in foreign jurisdictions exposing us to additional
challenges, such as foreign currency exchange rate fluctuations,
logistical and communications challenges, the burden and cost of
compliance with foreign laws, and political and/or economic
instabilities in specific jurisdictions; and (xv) market and other
conditions. More detailed information about the Company and the
risk factors that may affect the realization of forward looking
statements is set forth in the Company’s filings with the
Securities and Exchange Commission (SEC), including the Company’s
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents
free of charge on the SEC’s web site at: http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events, or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220119005234/en/
Investor Contacts: Brett Maas, Managing Principal, Hayden
IR, LLC brett@haydenir.com (646) 536-7331
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From May 2024 to Jun 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Jun 2023 to Jun 2024